New Therapeutic Approaches for Multiple Myeloma

New Therapeutic Approaches for Multiple Myeloma

Episodes

Specialty:

All

Year:

All

EP. 1: New Thinking on Asymptomatic Myeloma

June 27th 2016

EP. 2: When to Treat Smoldering Myeloma

June 27th 2016

EP. 3: Transplant-Eligible Newly Diagnosed Myeloma

June 27th 2016

EP. 4: Carfilzomib As Part of Upfront Therapy in Multiple Myeloma

June 27th 2016

EP. 5: The Ongoing Role of Transplant in Multiple Myeloma

June 27th 2016

EP. 6: Risk Stratified Treatment; Maintenance or Not?

June 27th 2016

EP. 7: Upfront Therapy for Transplant -Ineligible Patients

June 27th 2016

EP. 8: Therapy Based on Rapid versus Slow Progression of Myeloma

June 27th 2016

EP. 9: Pomalidomide In Lenalidomide-Refractory Multiple Myeloma Patients

June 27th 2016

EP. 10: Sequencing Therapies for Multiple Myeloma

June 27th 2016

EP. 11: Daratumumab Revolutionizing How Myeloma Is Treated

June 27th 2016

EP. 12: Practical Information on Immunotherapy Use

June 27th 2016

EP. 13: MRD Monitoring in Multiple Myeloma

June 27th 2016

EP. 14: Emerging Therapies for Myeloma

June 27th 2016

EP. 15: Final Thoughts on Modern Treatment of Myeloma

June 27th 2016

Trending on OncLive

Five Under 5: Top Oncology Videos for the Week of 8/31/26

FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer

B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer

Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC

The OncFive: Top Oncology Articles for the Week of 8/30